+339.0%
MCK vs MRNA
-67.9%
+406.9%
-27.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | +5.4% | -5.3% | +0.1% |
| 7D | -2.9% | -1.1% | -1.8% | -2.9% |
| 30D | +0.4% | +126.1% | -125.7% | +2.7% |
| 3M | +12.1% | +190.0% | -177.9% | +15.1% |
| 6M | -5.4% | +157.2% | -162.7% | -3.0% |
| YTD | +7.8% | +388.2% | -380.4% | +11.3% |
| 1Y | +22.9% | +467.0% | -444.1% | +27.2% |
| 3Y | +110.7% | +36.1% | +74.7% | +116.4% |
| All | +339.0% | -67.9% | +406.9% | +349.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling